Meeting Banner
Abstract #3121

Optimized CEST acquisition and analysis for treatment assessment of response to neoadjuvant chemotherapy in triple negative breast cancer

Shu Zhang1, Abeer H. Abdelhafez2, Jong Bum Son3, Benjamin C. Musall3, Mitsuharu Miyoshi4, Xinzeng Wang5, Ken-Pin Hwang3, Gaiane M. Rauch2, Jingfei Ma3, and Mark D. Pagel1
1Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 4Global MR Applications & Workflow, GE Healthcare Japan, Tokyo, Japan, 5Global MR Applications & Workflow, GE Healthcare, Houston, TX, United States

In our ongoing study of 13 completed patients, we compared two saturation power levels (2.0 μT vs. 0.9 μT) and two analysis methods (MTRasym vs. Lorentzian line fitting) of CEST for assessing treatment response to neoadjuvant chemotherapy of triple-negative breast cancer (TNBC). A consistently decreasing trend of the CEST signals was observed with the longitudinal treatment when a higher saturation power of 2.0 μT was used with the amide MTRasym analysis method. In contrast, the same trend was observed when a lower saturation power of 0.9 μT was used for the Lorentzian line fitting analysis method.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here